<bill session="114" type="h" number="2443" updated="2015-08-08T06:39:43-04:00">
  <state datetime="2015-05-19">REFERRED</state>
  <status>
    <introduced datetime="2015-05-19"/>
  </status>
  <introduced datetime="2015-05-19"/>
  <titles>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to CLIA waiver study design guidance for in vitro diagnostics.</title>
  </titles>
  <sponsor id="412278"/>
  <cosponsors/>
  <actions>
    <action datetime="2015-05-19" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2015-05-22">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="114" type="h" number="6"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
  </subjects>
  <amendments/>
  <summary>5/19/2015--Introduced.
This bill requires the Department of Health and Human Services to publish guidance that revises &#8220;Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices&#8221; and includes guidance on using comparable performance between types of users to demonstrate the accuracy of a medical device.</summary>
</bill>
